This trial is active, not recruiting.

Condition asthma
Treatment l-citrulline
Phase phase 1/phase 2
Sponsor University of Pittsburgh
Start date September 2013
End date June 2016
Trial size 10 participants
Trial identifier NCT01715844, L-citrulline Asthma


In people who develop asthma after the age of 12 and who are also overweigh, there can be an increased burden of asthma symptoms, more flare-ups, and poorly-controlled asthma when compared to normal weight asthmatics. Certain factors are more abundant in the blood of individuals who are obese. One such factor is derived from the metabolism of an amino acid found in your diet, which is known as L-arginine (Amino acids are most commonly known as the building blocks of proteins, the same as the proteins found in food). This factor is called asymmetric dimethylarginine or ADMA. The balance of L-arginine to ADMA may be important to the health of subjects with asthma. The balance between L-arginine and ADMA plays an important role in producing nitric oxide (NO) in the airways. NO is normally produced in the lung and plays a major role in maintaining airways open and functioning normally. Our research has shown that in subjects with asthma who are overweight and developed asthma later in life, the combination of low L-arginine and high ADMA, may lead to lower NO levels. We are asking participants in this study to take L-citrulline, which is converted to L-arginine by your body, as a supplement for a period of one week. We anticipate that L-citrulline will restore NO levels in the airways, by increasing the ratio of L-arginine to ADMA

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking double blind (subject, caregiver, investigator, outcomes assessor)
(Active Comparator)
3-gr/day of L-citrulline effervescent powder mix
l-citrulline L-citrulline 3 gr efervescent powder
Patients will take 3-gr of L-citrulline/day for 7 days
(Placebo Comparator)
3 gr of Placebo/day matching L-citrulline effervescent powder
l-citrulline L-citrulline 3 gr efervescent powder
Patients will take 3-gr of L-citrulline/day for 7 days

Primary Outcomes

Exhaled nitric oxide
time frame: 1 week

Secondary Outcomes

Sputum and plasma L-arginine/ADMA levels
time frame: 1 week

Eligibility Criteria

Male or female participants from 18 years up to 75 years old.

Inclusion Criteria: - Male and female patients, 18-75 yrs old, from all racial/ethnic backgrounds - Diagnosis of asthma for >1 yr - BMI ≥ 30 - Baseline pre-bronchodilator FEV1 between 60 and 90% predicted with a 12% or greater bronchodilator response to 4 puffs of albuterol - Smoking history <20 pack years and no smoking in the last year - Able to identify age of asthma onset Exclusion Criteria: - Respiratory tract infection within the last 4 weeks; - Oral CS burst within the last 4 weeks or regular systemic CS use - Hospitalization within the last 3 months - ER visit within the 4 weeks - Significant or uncontrolled concomitant medical illness including (but not limited to) heart disease, cancer, diabetes - Current smoking or within the previous 12 months - Current use of statins for the past 30 days (Statins lower ADMA levels) - Pregnancy - Intolerance or allergy to L-arginine or L-citrulline - Phosphodiesterase inhibitors - Taking oral nitrates

Additional Information

Official title L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
Principal investigator Fernando Holguin, MD MPH
Trial information was received from ClinicalTrials.gov and was last updated in January 2016.
Information provided to ClinicalTrials.gov by University of Pittsburgh.